

VICURON PHARMACEUTICALS INC

Form 8-K

May 28, 2004

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

**PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported):

May 24, 2004

Vicuron Pharmaceuticals Inc.

(Exact Name of Registrant As Specified in its Charter)

Delaware
(State or Other Jurisdiction

of Incorporation)

000-31145
(Commission File Number)

04-3278032
(I.R.S. Employer

Identification Number)

455 South Gulph Road, Suite 305, King of Prussia, PA 19406

(Address of Principal Executive Offices) (Zip Code)

(610) 205-2300

(Registrant's telephone number, including area code)

not applicable

(Former Name or Former Address, if Changed Since Last Report.)

Item 5. Other Events.

On May 24, 2004, Vicuron Pharmaceuticals Inc. announced that it received an approvable letter from the U.S. Food and Drug Administration. However, the letter indicated that Vicuron's New Drug Application submission for anidulafungin does not currently support a labeling claim for the initial treatment of esophageal candidiasis.

A copy of the press release relating to such announcement is attached to this Current Report on Form 8-K as Exhibit 99.1

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.

(c) Exhibits.

See Exhibit Index attached hereto.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

VICURON PHARMACEUTICALS INC.
(Registrant)

Date: May 27, 2004

By: /s/ George F. Horner III

George F. Horner III
President and Chief Executive Officer

EXHIBIT INDEX

Pursuant to Item 601(a)(2) of Regulation S-K, this Exhibit Index immediately precedes the exhibit.

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press release of Vicuron Pharmaceuticals Inc. dated May 24, 2004.